Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin 24 gene therapy in patients with advanced tumours.

Trial Profile

Interleukin 24 gene therapy in patients with advanced tumours.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interleukin 24 gene therapy-MultiVir (Primary)
  • Indications Solid tumours
  • Focus Pharmacodynamics
  • Sponsors MultiVir
  • Most Recent Events

    • 03 Mar 2014 Title is not official.
    • 03 Mar 2014 New trial record
    • 14 Feb 2014 Top-line results of a presentation at the Leerink Global Healthcare conference reported in a MultiVir media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top